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INTRODUCTION
Recurrent aphthous ulcerations (RAU) are common 
oral lesions that affect approximately 10% to 20% of the 
population. The disease is characterized by recurrent and 
painful ulcerations of the oral non-keratinized mucosa, 
which measure from 3 to 10 mm in diameter and heal 
without scarring in 7 to 14 days.1 The etiology of RAU 
remains unknown, but there is increasing evidence that 
its development has an immunogenic basis. The search 
for its cause should concentrate on disorders associated 
with immunoderegulation, decreased mucosal barriers, or 
conditions that elevate the antigenic stimulus. Major RAU 
have irregular margins, frequently exceed 10 mm in size, and 
typically leave scars.2
There have been many attempts over the years to find 
an effective treatment for RAU. Because the etiology of 
RAU remains unknown, its treatment consists of therapeutic 
measures to suppress its symptoms rather than bringing 
about a definitive cure. The therapeutic choice depends 
on the severity of the disease, which is measured by the 
frequency of ulcer recurrence, the number of ulcers, their 
location and duration, and the level of associated orofacial 
pain.3,4 Cases of major RAU that are characterized by pain, 
fever, and dysphagia and that are recurrent usually require 
systemic therapy. Several systemic drugs have been used 
to treat major RAU, including systemic corticosteroids, 
dapsone, colchicine, thalidomide, pentoxifylline, low-dose 
interferon-α, and levamisole.2,5
The use of systemic corticosteroids and immuno-
modulating agents has been the mainstay of treatment 
for major RAU. Intralesional steroid injections, which 
contain betamethasone dipropionate and betamethasone 
disodium phosphate, combined with levamisole therapy 
may successfully treat the large ulcers associated with major 
RAU.6
This paper presents a case report of major RAU where 
we tested the therapeutic efficacy of a treatment combining 
an intralesional corticosteroid and a drug used to modulate 
immune responses.
CASE REPORT
A 30-year-old woman presented a 15-year history of 
successive episodes of multiple major recurrent ulcers in the 
oral mucosa and tongue region of the mouth, which left scars 
after lesion regression. During the patient’s anamnesis, she 
reported having had these episodes since adolescence and 
having already been treated with corticosteroids, but without 
success. Clinical examination revealed symptomatic ulcers 
with perilesional erythematous halos that were covered 
with a pseudo membrane and located in the jugal mucosa 
and on the right side border of the tongue, exceeding 10 
mm in diameter (Fig. 1a). There were also areas of scarring 
on the right jugal mucosa. A clinical diagnosis of major 
RAU was made on the basis of the history and the clinical 
examinations. The other aspects of the patient’s medical 
history and family medical history were insignificant. 
Laboratory tests including a blood count analysis were 
performed to determine the levels of folic acid, iron, ferritin, 
as well as vitamins B2, B6, and B12, all of which showed 
normal results. 
The patient was subjected to a therapeutic consisting 651
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of prednisone (15 mg per day) and a topical mouthwash 
containing dexamethasone (20 mg per day) for two weeks, 
which was unsuccessful. Thus, a regimen was proposed 
consisting of an intralesional injection of betamethasone 
dipropionate (5 mg/ml) and betamethasone disodium 
phosphate (2 mg/ml) (Fig. 1b). After the first application, 
there was a partial regression of the lesions. Only one 
application was needed to bring about partial healing of 
the ulcers (Fig. 1c). To reduce the frequency of ulceration, 
levamisole hydrochloride (150 mg) was administered once 
a week for one month. Despite considerable improvement in 
the patient’s status, it has not yet been possible to precisely 
establish the etiologic agent. There was no recurrence during 
the 6-month follow-up period (Fig. 1d). 
DISCUSSION
The clinical features, etiology, and treatment of major 
recurrent aphthous ulcerations have been discussed. The 
primary goals of administering therapy for major RAU are 
to bring about relief from pain, reduction in ulcer duration, 
and the restoration of normal oral function. Secondary 
goals include a reduction in the frequency and severity 
of recurrences and the maintenance of remission. Topical 
medications, such as corticosteroids, can achieve the 
primary goals but have not been shown to alter recurrence 
or remission rates. Systemic medications can be combined 
with the topical therapy to achieve the secondary goals.7,8 
Levamisole, an antihelminthic drug that can modulate 
immune responses, has been used successfully as a 
monotherapy and as an adjunct to treatment in a variety 
of diseases. Because of its modulating effects on immune 
responses, levamisole has been used in a wide range of 
diseases with varying degrees of success. It has also been 
used in combination with corticosteroids to treat a number 
of mouth dermatologic disorders, such as major RAU.9,10 
The therapeutic method used in this case provided 
significant relief from symptoms and decreased the rate of 
recurrence. Additional studies are needed to evaluate the 
full potential of levamisole in oral dermatological diseases.
Figure 1 - (a) Major recurrent aphthous ulceration on the right border of the tongue; (b) intralesional injection of corticosteroids; (c) partial regression of 
the lesions was achieved one week after the administration of intralesional corticosteroids; (d) the major recurrent aphthous ulceration was resolved and 
no recurrence was observed after four weeks treatment with levamisole.652
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